WallStreetZenWallStreetZen

NASDAQ: AQST
Aquestive Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Aquestive Therapeutics revenue was $43.40M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $12.8M, up 28% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, AQST annual revenue was $57.6M, with 13.8% growth year-over-year.

AQST past revenue growth

How has AQST's revenue growth performed historically?

Company
-26.32%
Industry
2.44%
Market
22.05%
AQST's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
AQST's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
AQST's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

AQST revenue history

Current Revenue
$43.4M
Current Earnings
-$69.0M
Current Profit Margin
-158.9%

Be the first to know when AQST announces revenue.

AQST Revenue History By Year

AQST Yearly RevenueAQST RevenueAQST ChangeAQST Revenue Growth
2024-12-31$57.56M$6.98M+13.80%
2023-12-31$50.58M$2.90M+6.09%
2022-12-31$47.68M-$3.15M-6.20%
2021-12-31$50.83M$4.98M+10.87%
2020-12-31$45.85M-$6.76M-12.85%
2019-12-31$52.61M-$14.82M-21.98%
2018-12-31$67.43M$512.00k+0.77%
2017-12-31$66.92M$15.13M+29.22%
2016-12-31$51.79MN/AN/A

1 of 1

Aquestive Therapeutics Revenue FAQ

What was AQST's revenue last quarter?

On Invalid Date, Aquestive Therapeutics (NASDAQ: AQST) reported Q3 2025 revenue of $12.81 million up 5.43% year over year. In the same quarter last year, Aquestive Therapeutics's revenue was $13.54 million.

What was Aquestive Therapeutics's revenue in 2024?

Aquestive Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $57.56 million, a 13.8% increase year over year.

How much does Aquestive Therapeutics make in a day?

Based on Aquestive Therapeutics annual revenue for the past five years, AQST makes an average of $138,358.90 per day.

What was Aquestive Therapeutics's annual revenue growth in the past year?

As of Q4 2025, Aquestive Therapeutics's revenue has grown -26.32% year over year. This is 28.76 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 2.44%. Aquestive Therapeutics's revenue in the past year totaled $43.40 million.

How much does Aquestive Therapeutics make in a year?

Aquestive Therapeutics's revenue by year for the past five years is:
  • Aquestive Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $57.56 million, a 13.8% increase year over year.
  • Aquestive Therapeutics's annual revenue for Dec 31, 2023 was $50.58 million, a 6.09% increase from 2022.
  • Aquestive Therapeutics's annual revenue for 2022 was $47.68 million, a 6.2% decrease from 2021.
  • Aquestive Therapeutics's annual revenue for 2021 was $50.83 million, a 10.87% increase from 2020.
  • Aquestive Therapeutics's annual revenue for 2020 was $45.85 million, a 12.85% decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.